BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
Open Access
- 7 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e65489
Abstract
Based on promising preclinical efficacy associated with the 20S proteasome inhibitor bortezomib in malignant pleural mesothelioma (MPM), two phase II clinical trials have been initiated (EORTC 08052 and ICORG 05–10). However, the potential mechanisms underlying resistance to this targeted drug in MPM are still unknown. Functional genetic analyses were conducted to determine the key mitochondrial apoptotic regulators required for bortezomib sensitivity and to establish how their dysregulation may confer resistance. The multidomain proapoptotic protein BAK, but not its orthologue BAX, was found to be essential for bortezomib-induced apoptosis in MPM cell lines. Immunohistochemistry was performed on tissues from the ICORG-05 phase II trial and a TMA of archived mesotheliomas. Loss of BAK was found in 39% of specimens and loss of both BAX/BAK in 37% of samples. However, MPM tissues from patients who failed to respond to bortezomib and MPM cell lines selected for resistance to bortezomib conserved BAK expression. In contrast, c-Myc dependent transactivation of NOXA was abrogated in the resistant cell lines. In summary, the block of mitochondrial apoptosis is a limiting factor for achieving efficacy of bortezomib in MPM, and the observed loss of BAK expression or NOXA transactivation may be relevant mechanisms of resistance in the clinic.Keywords
This publication has 47 references indexed in Scilit:
- Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat lineExperimental Hematology, 2008
- Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 proteinBlood, 2008
- Point Mutation of the Proteasome β5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia LineThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Advances in the systemic therapy of malignant pleural mesotheliomaNature Clinical Practice Oncology, 2008
- Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunitsCancer, 2008
- Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicityMolecular Cancer, 2008
- BCL-2 family regulation by the 20S proteasome inhibitor bortezomibOncogene, 2007
- Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesotheliomaCancer Chemotherapy and Pharmacology, 2007
- Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cellsJournal of Cellular Biochemistry, 2007
- Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293T Cell–Based SystemsCurrent Protocols in Immunology, 1999